In a recent move, the Trump administration made headlines by taking what it described as “bold actions” related to autism, primarily promoting leucovorin, a generic medication, as a potential treatment for children with autism spectrum disorder. During a press event at the White House, Marty Makary, the commissioner of the Food and Drug Administration (FDA), asserted that there was a “growing body of evidence” indicating that leucovorin might be beneficial for this demographic. He speculated that the drug could help “20, 40, 50 percent of kids with autism,” which he believed could translate into benefits for hundreds of thousands of children.
The administration’s claims about leucovorin attracted significant attention, leading to a notable increase in prescriptions. A study published in The Lancet revealed that new outpatient prescriptions of leucovorin for children aged 5 to 17 surged by 71 percent in the three months following the administration’s announcements.
However, the aftermath of these bold assertions took an unexpected turn. Senior officials from the FDA clarified that they did not share the same optimism regarding the drug’s efficacy for autism. In an official announcement, the FDA confirmed its approval of leucovorin solely for treating a rare genetic condition known as cerebral folate deficiency (CFD), specifically in adult patients who have a genetic mutation linked to the folate receptor 1 gene. The agency stated that it found insufficient evidence to support extending leucovorin’s application to autism treatment.
The discrepancy between the administration’s bold claims and the FDA’s cautious stance raised questions about the basis for the initial promotion of leucovorin as a treatment for autism. The development highlights ongoing complexities surrounding autism treatment options, the role of regulatory bodies, and the implications of public health messaging. As discussions continue, the evidential requirements and regulatory processes governing the approval of new treatments remain crucial focal points in the healthcare dialogue.
